The NUCRYST Pharmaceuticals' management team has a broad base of pharmaceutical and medical device management experience, including product development and launches of major pharmaceutical products and medical devices.
Scott H. Gillis - Paul J. Schechter, MD, PhD - David C. McDowell - Eliot M. Lurier
Scott H. Gillis
President, NUCRYST Pharmaceuticals
Mr. Gillis joined NUCRYST in 1999 at an important stage for the company. Through his leadership, NUCRYST entered into a collaborative agreement with Smith & Nephew for the global sale and distribution of Acticoat™ antimicrobial dressings. In 2001, NUCRYST diversified its direction to embrace pharmaceutical product development. Under his guidance, the company has grown from 57 to 130 employees, expanded its manufacturing twice, established a pharmaceutical research facility and placed its first drug into clinical trial.
Mr. Gillis has more than 30 years experience in the pharmaceutical and medical device industry in capacities ranging from pharmaceutical sales to senior sales and marketing positions to general management with extensive experience in the fields of dermatology, anti-infective, cardiovascular, oncology, psychiatric, orthopedic and wound care products. His experience also includes the advancement of medical ideas from research and development to commercial products, sourcing and securing financing, and negotiating sales, marketing and distribution partnerships with major healthcare corporations.
Prior to joining NUCRYST in 1999, Mr. Gillis served as President and CEO of Li Medical, a medical device company. Prior to Li Medical Mr. Gillis spent 15 years at Bristol-Myers Squibb where he worked in a number of divisions including Squibb, Westwood, Mead Johnson Pharmaceuticals, ConvaTec and Mead Johnson Oncology. At ConvaTec he served as Vice President and General Manager of ConvaTec USA and later as Global Vice President, Wound and Skin Care.
A Boston native, Mr. Gillis has an MBA from Xavier University and a BA in Biology and Chemistry from Salem State College.
Paul J. Schechter, MD, PhD
Vice President of Drug Development & Regulatory Affairs
Chief Medical Officer
Dr. Schechter, who joined NUCRYST in 2002, has spearheaded the move into pharmaceutical research. His accomplishments include establishing a formal scientific advisory board, expanding NUCRYST's R&D to include pharmaceutical products, and introducing the first product into clinical trial.
Prior to NUCRYST, Dr. Schechter served as Vice President, Drug Development and Regulatory Affairs at MacroChem Corporation, where he established and managed drug development and regulatory processes for topical/transdermal agents. He also held senior research and development and drug development roles at Fujisawa Pharmaceutical Company, Hybridon, Inc., a Massachusetts biotech company, and Merrell Dow, where he guided a number of new chemical entities through Phase 1,2 and 3 clinical trials to regulatory approval. Dr. Schechter began his career at the National Institutes of Health in Bethesda, Maryland.
Dr. Schechter received his MD and PhD in Pharmacology from the University of Chicago. He has published more than 140 papers in the fields of biochemistry, pharmacology, pharmacokinetics, drug metabolism and clinical medicine, and has seven US published patents. He has been elected to membership in numerous professional societies in the United States and abroad.
David C. McDowell
Vice President of Operations
Mr. McDowell joined NUCRYST in July of 2005 to lead the company's sales, supply and new product development effort in the burn and wound care markets. He oversees NUCRYST's quality, engineering, manufacturing, medical coatings research and wound care product development. He brings more than 25 years of management experience in the pharmaceutical, medical device and consumer packaged goods industry, both domestic and international.
Prior to joining NUCRYST, Mr. McDowell served in senior positions with Novartis, GlaxoSmithKline and Sterling Winthrop. Most recently, he held the position of General Manager Sterile Manufacturing, Head Lens Care Products Global Supply with CIBA Vision, a Novartis company, where he was responsible for global manufacturing and supply of lens care and eye care products.
Mr. McDowell is based at NUCRYST's facility in Fort Saskatchewan, Alberta, Canada. He earned a BASC in Industrial Engineering from the University of Toronto.
Eliot M. Lurier
Vice President of Finance and Administration
Mr. Lurier joined NUCRYST in April of 2005 as Vice President, Finance & Administration. He is based in Wakefield and brings more that 20 years experience in corporate finance, including 11 years with early stage pharmaceutical companies.
Prior to joining NUCRYST, Mr. Lurier specialized in building financial and operational infrastructure for emerging life science companies. He has extensive experience in raising capital in the public and private sector. Mr. Lurier previously served as Chief Financial Officer and Vice President, Finance of Ascent Pediatrics Inc. and as Consulting Chief Financial Officer to Bridge Pharmaceuticals Inc. and Linden Bioscience Inc.
Mr. Lurier earned a Bachelor of Science, Accounting from Syracuse University and is a certified public accountant in Massachusetts.